Board of Directors

EXECUTIVE COMMITTEE

Jeanine D’Armiento, MD, PhD
Chair
New York

Elizabeth Johnson
Vice Chair
Massachusetts

Fred C. Walsh
2nd Vice Chair
Massachusetts

Jennifer Jopp
Secretary
Minnesota

Jon Hagstrom
Treasurer
New York

Martin R. Zamora, MD
Physician-Director
Colorado

BOARD MEMBERS

Faron Schonfeld
Pennsylvania

Kenneth Irvine
Connecticut

Peggy Iverson
Iowa

Ann Knebel, PhD, RN
Maryland

Noel G. McElvaney, MD,
BCh, BAO, FRCP, FRCPC
Ireland

James K. Stoller, MD
Ohio
Our accomplishments and accreditations reflect our unparalleled commitment to medical research at its finest: we have invested over $91 million to support Alpha-1 research and programs at 123 institutions in North America, Europe, South America, the Middle East, and Australia. These innovative, impactful projects have built a solid infrastructure for promoting ongoing research and the development of new therapies. We have also fostered collaborations with investigators throughout the United States and Europe, working closely with the pharmaceutical industry, the National Institutes of Health (NIH), the U.S. Food and Drug Administration (FDA), and Alpha-1 patients and families.

There are more advancements on the horizon than ever before and our commitment to fund vital research needed to make breakthroughs in Alpha-1 is greater than ever. The Alpha-1 Research Registry is growing with enthusiastic Alphas who are ready to advance the Foundation’s research goals.

During this fiscal year, we welcomed a new President and Chief Executive Officer, Scott Santarella. Scott joined the Foundation in September 2021, with over 25 years of experience as a senior executive. Scott’s vision for the Alpha-1 Foundation included the continuation of achievement through forward momentum, the optimism of forward-thinking through innovation, and the advancement of impact through forward progress.

“Now is the time to accelerate our efforts across the spectrum and maximize our resources to expedite progress toward our ultimate goal – a cure,” said Santarella. “It is here that patients play the most vital role. The key to solving the Alpha-1 puzzle will be found in the patient.”

We utilized innovative and creative ways to connect the community through this part of the pandemic. Hybrid event options transformed the way we served the community in all of our programs. A COVID event grid was created to provide a framework on how to resume in-person events while keeping the safety of Alphas a top priority. We were able to host the annual Alpha-1 National Conference in a hybrid fashion in 3 cities across the United States, assuming a unique blend of online presentations using our robust virtual environment with interactive features. This was just the first step in our path to a “new normal.”
Our website, www.alpha1.org, is a clearinghouse for information on Alpha-1 providing educational resources, highlighting news and upcoming events, and creating opportunities for virtual connection within the global Alpha-1 community. We maintain content targeted toward several different audiences, including newly diagnosed Alphas, family members and caregivers, healthcare providers, researchers, and industry partners. The website received over 484,000 visits from over 234,000 unique visitors in FY 2022. The Alpha-1 Foundation’s website is most often the first contact that newly diagnosed Alphas and their family members have with the Foundation and in many cases, their first source of information about Alpha-1 Antitrypsin Deficiency.

We connect with the Alpha-1 community across multiple social media platforms. In addition to promoting new Foundation initiatives, community education events, and fundraising campaigns, our presence on Facebook, Instagram, and Twitter has directly increased traffic to our website, where users can access the information they need.

The monthly Community Currents electronic newsletter keeps the Alpha-1 community and volunteer leadership updated on all Alpha-1-related news, upcoming events, research, programs, fundraising activities, and the Alpha-1 Research Registry.

The Alpha-1-to-One Magazine is a valued resource produced three times a year for the Alpha-1 community offering practical advice, personal experiences, and pertinent news for people touched by Alpha-1. In FY 2022, we distributed 30,000 printed copies of each issue, including bundles to Clinical Resource Centers (CRCs) and healthcare providers; each issue is also posted to a digital publishing platform on our website, where it is accessed by nearly 2,000 more visitors a year. In the Fall issue of the magazine "All In For Alpha-1" spotlighted the 2021 Virtual Alpha-1 National Conference. In the Winter issue "Riding for a Reason" focused on the 25th anniversary of Escape to the Cape Bike Trek. The Spring issue’s theme “Forward Momentum” welcomed Scott Santarella as the new President and CEO of the Alpha-1 Foundation.
Our advocates are a voice to improve outcomes for Alpha-1 patients. Together, we are fighting to improve the fact that Alpha-1 is under-recognized, under-diagnosed, and unknown to most people by ensuring our community’s priorities are factored into public policy and legislation. Our advocacy program targets policymakers, regulatory agencies, the public, and the media with campaigns to promote research and raise awareness of the challenges faced by Alpha-1 patients and care providers. Our FY 2022 policy priorities included access to care, medical research, therapeutic development, screening and detection, federal and state funding, blood product safety, and education and awareness.

We worked with Congress to find a solution to the patient access problem facing Medicare beneficiaries who are not able to obtain a home infusion. In March 2022, the John W. Walsh Home Infusion Act introduced a permanent benefit for Alphas to receive augmentation therapy in the home setting through Medicare Part B. This process is ongoing, and we continue to work diligently with advocates and legislators to meet the needs of the Alpha-1 community.

We work strategically with federal agencies, memberships, and coalitions—focusing on the issues that matter most to Alphas—to inform legislators of the burdens of the patient community and to advance our public policy agenda for the benefit of the Alpha-1 community.

Additionally, working closely with the U.S. Food and Drug Administration (FDA), Critical Path Institute (C-Path), and National Institutes of Health (NIH).

- November 10, 2021, Fall Virtual Lobby Day
- Fall Advocacy Training Series
- 2022 Rare Disease Day
The Alpha-1 National Education Series is comprised of regional Alpha-1 Education Days for Alphas, their families, and caregivers. These one-day educational programs provide access to current medical information, timely topics affecting Alphas, resources from leading Alpha-1 experts, and opportunities to connect with the Alpha-1 community.

In 2022, we continued our use of a virtual event platform, enabling those who were unable to attend an Alpha-1 Education Day in person to participate and connect with the Alpha-1 community. Extending our education series into the virtual space has also created community-building and engagement opportunities through more direct access to social media, polls, and surveys.

More than 2,300 people registered for the FY 2022 Alpha-1 Education Days.
After two years of completely virtual programming, we were proud to announce that the first-ever Hybrid Alpha-1 National Conference was held on June 2022. The format of the Hybrid Alpha-1 National Conference was meticulously crafted in a way that sought to combine the best aspects of the traditional in-person format while also continuing to provide the accessibility and flexibility offered by a virtual format. Three sites were selected to represent major regions in the United States: New York City, Miami, and Oregon. Each site is also home to one of the Foundation's Clinical Resource Centers (CRCs), specialized locations that give patients access to doctors who are familiar with Alpha-1. The four-day agenda was packed with engagement and interaction, including three Platinum Sponsor live events, three phenomenal keynote speakers, eighteen open forum question and answer breakout sessions, three live panel sessions, and on-demand education sessions throughout the conference. Presentations from the conference were available to view on-demand on the Foundation’s Vimeo channel.

Stats: 1,195 registered to attend
667 attended from 47 states and 10 countries
510 patients and family members
53 medical professionals
23% of first-time attendees
Meetings and Conferences

Scientific meetings and conferences organized by the Alpha-1 Foundation generate awareness of Alpha-1, identify new areas of research interest, and establish the Foundation’s credibility within the rare disease community as a resource for serious research, education, and advocacy.

The 23rd Gordon L. Snider Critical Issues Workshop entitled "Liver Biomarkers and the Path to Alpha-1 Liver" was held on November 19, 2021. The overall goal of the workshop was to bring together researchers, clinicians, and industry representatives to focus on identifying biomarkers to support the path to drug approval in liver disease. Co-chaired by Virginia Clark, MD, MS from the University of Florida and Pavel Strnad, MD from University Hospital/Aachen.

"Outstanding speakers and the co-chairs brought into sharp focus both challenges and pathways to drug approval in a new era of drugs to treat Alpha-1 Antitrypsin Deficiency related liver disease," stated Dr. Mark Brantly, Alpha-1 Foundation Scientific Director.

We reach thousands of physicians, academic researchers, and industry partners each year through our exhibitions at major national and international medical conferences, where we share insights into new technologies, research findings, and priority research areas.

The CRC Forum took place on June 30, 2022, and was an opportunity to engage Alpha-1 physician specialists and leaders in the field of Alpha-1 research and the patient community to learn about new Foundation programs, research initiatives, and updates from industry sponsors.
Annual campaigns help facilitate community support and improved approaches to care.

#Alpha1Awareness - November is Alpha-1 Awareness Month: 30 days of awareness-focused initiatives, through which the Alpha-1 community shares stories and resources while raising funds to support the search for a cure. A dedicated webpage, online training, digital resources, media outreach, community events, and a social media calendar are available throughout November specifically for awareness. The 2021 Alpha-1 Virtual Walks allowed anyone who wanted to make a difference in the Alpha-1 community to contribute in their own style, time, and pace. Over 700 participants tracked miles on STRAVA and raised over $72,000 for Alpha-1 in just one month.

#RareDiseaseDay - During the month of February, we collaborated with the National Organization for Rare Disorders (NORD) to spread awareness of Alpha-1 on Rare Disease Day. The goal was to get patients interested and involved in rare disease research.
Family Testing

Alpha-1 Coded Testing (ACT) Study has enrolled over 47,000 individuals since collecting data on the impact of at-home confidential genetic testing. The ACT study is a confidential testing program aimed at those who are at risk of Alpha-1, it provides an opportunity for individuals and their family members to be tested for Alpha-1 in the privacy of their homes, without the concern for health and life insurance issues associated with a diagnosed pre-existing condition.

The study screened 1,897 people in FY 2022 and 52% of those tested were identified as carriers of Alpha-1 and 5% were diagnosed as ZZ Alphas.
Community Fundraisers

Our Building Friends for a Cure (BFC) community fundraisers are designed to increase awareness and promote research. Support from the Alpha-1 community is a critical component of our goal to raise awareness of the disease and treatment options. Through the BFC program, we steward relationships with donors to boost awareness of Alpha-1 and get the community involved in working towards a cure.

Building Friends for a Cure consisted of a series of community fundraising events this year in support of Alpha-1 research, including:

- Riding for a Reason
- Escape to the Cape
- Alpha-1 Virtual Walks
- Celtic Connection
- Walks, Run, and Marathons
- Alpha Hours
- Climbs and Hikes
- Video Game Streaming Marathons
- Golf Tournaments
Research Grant Awards

The Alpha-1 Foundation directed more than $2 million in peer-reviewed research grants in FY 2022. These grants support innovative research spanning the spectrum of scientific discovery. The Foundation prides itself on being the #1 funders in Alpha-1 research having invested over $90 million at 128 institutions in 14 countries worldwide. Research funded by the Alpha-1 Foundation has improved our understanding of the mechanisms underlying the clinical manifestations of Alpha-1 and identified novel drug targets likely to lead to new therapeutic solutions.

The Foundation is proud to announce its in-cycle grant awardees for 2022, with 11 grant recipients receiving over $2 million for their projects. Of this year’s grant recipients’ fields of study, 45.5% were lung focused, 36.4% were liver-focused and 18.2% were focused in both areas. The research was focused 72.7% on basic research and 27.3% on translational research, keeping a well-rounded portfolio.

Brian Hobb, MD  
Brigham and Women’s Hospital  
“Inflammatory Protein Biomarkers of Reduced Lung Function in AATD”

Joseph Kaserman, MD  
Boston University  
“Mechanisms of Hepatic Heterogeneity and ATF6 Mediated Metabolic Dysfunction in AATD”

Jarrett Morrow, PhD  
Brigham and Women’s Hospital  
“Blood and Lung Microbiome in Alpha-1 Antitrypsin Deficiency”

Pasquale Piccolo, PhD  
Telethon Institute of Genetics and Medicine  
“Mitochondrial Dysfunction in Alpha-1 Antitrypsin Deficiency Associated Liver Disease”
Francesco Annunziata, PhD
Telethon Institute of Genetics and Medicine (TIGEM)
Naples, Italy

“Severity and progression of airway dropout in AAT knockout transgenic ferret model of COPD”

Shah Hussain, PhD
University of Alabama at Birmingham

“Identification and Modulation of Local and Systemic Environmental Factors in AATD”

George Sophocleous, PhD
University College London

“Structural and biophysical dissection of the alpha-1 antitrypsin polymerization pathway”

Lisa Carita, PhD, BSc
University College London

“Modulating the Co-Translational Misfolding and Polymerization of Antitrypsin”

Tomas Carroll, PhD
Royal College of Surgeons in Ireland

“A Family Affair- Clarifying the Risk of Lung Disease in ZZ AATD”

Valerie Gouon-Evans, PhD
Boston Medical Center

“Longitudinal Evaluation of Lung Disease Progression in PIMZ Patients”

Monica Goldklang, MD
Columbia University Irving Medical Center

“Engineered and Edited Patient-Derived iPSC for AATD-Associated Liver Disease Cell Therapy”
## Statement of Financial Position

### Current Assets

<table>
<thead>
<tr>
<th>Asset</th>
<th>2022</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$12,377,362</td>
<td>$8,614,083</td>
</tr>
<tr>
<td>Investment securities</td>
<td>$16,836,191</td>
<td>$18,369,431</td>
</tr>
<tr>
<td>Accounts receivable</td>
<td>$675,117</td>
<td>$982,721</td>
</tr>
<tr>
<td>Other current assets</td>
<td>$167,500</td>
<td>$21,728</td>
</tr>
<tr>
<td>Total Current Assets</td>
<td>$30,056,170</td>
<td>$27,987,963</td>
</tr>
</tbody>
</table>

### Investment Securities - Non-Current

<table>
<thead>
<tr>
<th>Asset</th>
<th>2022</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Investment securities - non-current</td>
<td>$5,039,394</td>
<td>$6,432,525</td>
</tr>
</tbody>
</table>

### Investment in TAP

<table>
<thead>
<tr>
<th>Asset</th>
<th>2022</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Investment in TAP</td>
<td>$363,069</td>
<td>$136,115</td>
</tr>
</tbody>
</table>

### Property and Equipment, Net

<table>
<thead>
<tr>
<th>Asset</th>
<th>2022</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Property and equipment, net</td>
<td>$12,983</td>
<td>$21,749</td>
</tr>
<tr>
<td>Other assets</td>
<td>$25,000</td>
<td>$25,134</td>
</tr>
<tr>
<td>Total assets</td>
<td>$35,496,616</td>
<td>$34,603,486</td>
</tr>
</tbody>
</table>

### Current Liabilities

<table>
<thead>
<tr>
<th>Liability</th>
<th>2022</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>$1,908,720</td>
<td>$1,951,672</td>
</tr>
<tr>
<td>Refundable advances</td>
<td>$505,000</td>
<td>$130,000</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>$210,000</td>
<td>$286,000</td>
</tr>
<tr>
<td>Total current liabilities</td>
<td>$2,623,720</td>
<td>$2,367,672</td>
</tr>
</tbody>
</table>

### Net Assets

<table>
<thead>
<tr>
<th>Asset</th>
<th>2022</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Without donor restrictions</td>
<td>$28,669,884</td>
<td>$29,114,292</td>
</tr>
<tr>
<td>With donor restrictions</td>
<td>$3,303,012</td>
<td>$3,121,522</td>
</tr>
<tr>
<td>Total net assets</td>
<td>$32,872,896</td>
<td>$32,235,814</td>
</tr>
<tr>
<td>Total liabilities and net assets</td>
<td>$35,496,616</td>
<td>$34,603,466</td>
</tr>
</tbody>
</table>
## Statement of Activities & Changes in Net Assets

<table>
<thead>
<tr>
<th>Changes in net assets without donor restrictions</th>
<th>2022</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions, bequests and grant revenues</td>
<td>$6,211,034</td>
<td>$5,385,961</td>
</tr>
<tr>
<td>Donated securities</td>
<td>-</td>
<td>$10,230</td>
</tr>
<tr>
<td>Fundraising revenues</td>
<td>$49,150</td>
<td>$52,684</td>
</tr>
<tr>
<td>Net realized and unrealized investment (losses)/gains</td>
<td>($3,267,543)</td>
<td>$4,778,951</td>
</tr>
<tr>
<td>Interest and dividends</td>
<td>$465,634</td>
<td>$460,729</td>
</tr>
<tr>
<td>In-kind rental income</td>
<td>$210,000</td>
<td>$200,000</td>
</tr>
<tr>
<td>Net assets released from restriction</td>
<td>$2,447,606</td>
<td>$1,816,820</td>
</tr>
<tr>
<td>Other Income</td>
<td>$374,788</td>
<td>$248,788</td>
</tr>
<tr>
<td><strong>Total support/revenue without donor restrictions</strong></td>
<td><strong>$6,490,669</strong></td>
<td><strong>$12,954,163</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Expenses</th>
<th>2022</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research and Clinical Studies</td>
<td>$3,450,654</td>
<td>$3,713,401</td>
</tr>
<tr>
<td>Patient Education</td>
<td>$1,197,628</td>
<td>$1,075,527</td>
</tr>
<tr>
<td>Patient Advocacy</td>
<td>$429,678</td>
<td>$288,876</td>
</tr>
<tr>
<td><strong>Total program services</strong></td>
<td><strong>$5,077,960</strong></td>
<td><strong>$5,077,804</strong></td>
</tr>
<tr>
<td>Administrative and general</td>
<td>$555,657</td>
<td>$492,150</td>
</tr>
<tr>
<td>Fund raising</td>
<td>$628,414</td>
<td>$550,275</td>
</tr>
<tr>
<td><strong>Total supporting services</strong></td>
<td><strong>$1,184,071</strong></td>
<td><strong>$1,042,425</strong></td>
</tr>
<tr>
<td><strong>Total expenses</strong></td>
<td><strong>$6,262,031</strong></td>
<td><strong>$6,120,229</strong></td>
</tr>
<tr>
<td>Change attributed to income (loss) from TAP</td>
<td>$226,954</td>
<td>$1,427</td>
</tr>
<tr>
<td>Increase in net assets without donor restrictions</td>
<td>$455,592</td>
<td>$6,835,361</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Changes in net assets without donor restrictions</th>
<th>2022</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions, bequests and grant revenues</td>
<td>$2,629,096</td>
<td>$2,343,702</td>
</tr>
<tr>
<td>Net assets released from restriction</td>
<td>($2,447,606)</td>
<td>($1,816,820)</td>
</tr>
<tr>
<td>Increase in net assets with donor restrictions</td>
<td>$181,490</td>
<td>$526,882</td>
</tr>
<tr>
<td>Increase in net assets</td>
<td>$637,082</td>
<td>$7,362,243</td>
</tr>
<tr>
<td>Net assets, beginning of year</td>
<td>$32,235,814</td>
<td>$24,873,571</td>
</tr>
<tr>
<td>Net assets, end of year</td>
<td>$32,872,896</td>
<td>$32,235,814</td>
</tr>
</tbody>
</table>
The Alpha-1 Foundation is committed to finding a cure for Alpha-1 Antitrypsin Deficiency (Alpha-1) and improving the lives of people affected by Alpha-1 worldwide. The Alpha-1 Foundation has invested more than $91 million to support Alpha-1 research and programs at more than 123 institutions in North America, Europe, the Middle East, and Australia.

The Alpha-1 Research Registry is a confidential database of people with Alpha-1 (Alphas) and Alpha-1 carriers. It is a resource for investigators seeking Alphas to participate in clinical trials, surveys, and other scientific and medical activities. For more information, email alpha1registry@alpha1.org or call toll-free 1-877-228-7321 ext. 252. https://www.alpha1.org/alphas-friends-family/resources/participate-in-research/.

Alpha-1 Coded Testing provides free, confidential testing administered through a research study that evaluates the perceived risks and benefits of genetic testing. For more information, email alphallab@alphaone.ufl.edu or call toll-free 1-855-476-1227 https://www.alpha1.org/healthcare-providers/testing-and-treatment/alpha-1-coded-testing-study/.

The Support Network is comprised of over 80 support groups nationwide that provide guidance and education to Alphas and family members, create awareness in local communities, and advocate for national and state issues that affect Alphas. Four Virtual Support Groups provide a forum for topics such as Alpha-1 Kids, Pre & Post Transplant issues, Caregivers, and Timely Topics. To find a support group near you, visit a1f.org/support-groups.

The Patient Information Line 1-800-245-6809 is available free of charge to anyone affected by Alpha-1 and provides support and answers to topics such as Alpha-1 testing, emotional impact, and physician and support group referrals.

The Genetic Counseling Program 1-855-476-1227, based at the University of Florida, is a free and confidential service that provides direct contact with a genetic counseling service to provide information on the risks and benefits of testing for Alpha-1, interpreting test results, understanding the genetics of Alpha-1, and other issues associated with having a genetic illness. https://www.alpha1.org/alphas-friends-family/support/genetic-counseling/

The Peer Guide Program 1-877-346-3212 connects newly diagnosed Alphas with other Alphas who have a similar set of circumstances to provide emotional support, discuss resources available, and assist in making choices about health.
The Oxygen Fund provides oxygen equipment for Alphas in financial need to travel to physicians, hospitals, Alpha-1 educational events, and other activities. For more information contact Joy Collins at jcollins@alpha1.org or call 1-877-228-7321 ext. 251. https://www.alpha1.org/alphas-friends-family/resources/oxygen-resources/

Patient Education Programs include an annual National Education Conference which brings together over 600 Alphas, caregivers, industry representatives, clinicians, allied healthcare workers, and scientists to discuss a wide range of Alpha-1-related topics. For more information, visit alf.org/alpha1conference. Additionally, a series of Alpha-1 Education Days are held each year in various cities throughout the U.S. to bring patient education to a regional audience. For more information, visit alf.org/educationdays. Recordings of these events are available via E-Education at alf.org/education-videos.

Building Friends for a Cure is a program designed to nurture ongoing friendships in the Alpha-1 community. The goal is to increase awareness and raise funds for research and related programs which will ultimately lead to a cure for Alpha-1. By becoming involved in fundraising efforts, such as virtual events, letter-writing campaigns, and other social and sporting events, you are making a difference. Visit alf.org/building-friends, contact amcbride@alpha1.org, or call 1-877-228-7321 ext. 233 for more information.

The Alpha-1 Kids Program is geared to the special needs and concerns of parents of children with Alpha-1. A committee of volunteer parents helps direct the program, which consists of a hotline, age-appropriate informational books, a virtual support group, and a parent peer guide program. For more information, visit alf.org/alpha1-kids or contact Cathey Henderson at chenderson@alpha1.org.

Educational resources about Alpha-1 and related topics are available for Alphas, their families, caregivers, and healthcare providers. Informational brochures such as 'What is Alpha-1?', 'Am I an Alpha Carrier?', 'The Liver and Alpha-1', and 'It's All In The Family: Family Testing' are available to download and order through our website, alf.org/a1-publications, or by calling toll-free 1-877-228-7321 ext. 251. The Alpha-1 to One Magazine is published three times a year and includes timely articles about Alpha-1 research and Alpha life, as well as answers from Alpha-1 experts to questions from the Alpha-1 Community. Join the mailing list here at alpha1.org/alphas-friends-family/resources/join-mailing-list/ to receive the magazine. Presentations from previous Alpha-1 educational events are available via E-Education at alf.org/education-videos.
The Foundation’s Public Policy Program advocates for the Alpha-1 community by monitoring and influencing legislative and regulatory issues. Primary concerns include stimulating medical research, blood product safety, developing new therapies, screening, and detection, access to care and reimbursement, federal and state funding, education, awareness, and the recognition of the special needs of people with Alpha-1. For more information, contact Jeanne Kushner at jkushner@alpha1.org or call 1-877-228-7321 ext. 204 or visit a1f.org/action-alert.

Grants and Awards: The Foundation’s peer-reviewed grants program is intended to promote research that will lead to improved health for Alphas and ultimately, find a cure. We offer grants for both basic science and clinical research. For more information, contact Vanessa Valencia at vvalencia@alpha1.org or call 1-877-228-7321 ext. 242.

The Alpha-1 Foundation DNA & Tissue Bank at the University of Florida is the central storage site for DNA and tissue samples from Alphas and other donors. The Bank is a resource for researchers investigating Alpha-1 and other conditions. Researchers should contact Vanessa Valencia at vvalencia@alpha1.org or call 1-877-228-7321 ext. 242. For other information, call toll-free 1-866-284-2708.

The Targeted Detection Program promotes worldwide awareness among medical professionals, the media, and the public, and the identification of Alphas in population groups at risk. For further information, please call 1-877-228-7321 ext. 306.

The Alpha-1 Clinical Resource Center Network is a steadily growing group of centers throughout North America that specialize in patient care and education for those with Alpha-1. Centers also offer other resources for Alphas such as support groups, transplant centers, and pulmonary rehabilitation. Alphas and their physicians are encouraged to contact their regional Clinical Resource Center for information and guidance. To find an Alpha-1 specialist near you, visit a1f.org/alpha1doc. For more information, contact Vanessa Valencia at vvalencia@alpha1.org or call 1-877-228-7321 ext. 242.

Scientific Meetings, Conferences, Workshops, Working Groups, and Symposia bring scientists together to focus on special topics related to Alpha-1, advance knowledge of the genetic condition, and work toward new therapies and a cure. For more information, contact Adriana De Arce at adearce@alpha1.org or call 1-877-228-7321 ext. 269.
The Alpha-1 Global Initiative works on a global, national, and local level to enhance care and support for all those affected by Alpha-1. The Foundation is committed to providing reliable resources and information worldwide. As part of the Global Alpha-1 Initiative, the Foundation is creating new tools focusing on connecting Alphas all over the world with resources – and with each other. For more information, visit alpha-1global.org, contact Randel Plant at rplant@alpha1.org, or call 1-877-228-7321 ext. 306.

Access and Reimbursement: The Alpha-1 Foundation is committed to providing the tools and resources necessary to assist Alphas in making informed decisions about their healthcare plan and assistance program selection. Patients with questions or issues concerning access or reimbursement should contact Cathey Henderson at 1-800-245-6809 or chenderson@alpha1.org. https://www.alpha1.org/alphas-friends-family/resources/assistance-organizations/

The Clinical Trial Outreach and Education Program is an online tool used to educate Alphas about clinical trials with curated educational materials for Alpha-1. For more information, visit https://www.alpha1.org/alphas-friends-family/resources/clinical-trials/ or contact Alison Keaveny at akeaveny@alpha1.org or call 1-877-228-7321 est. 206.
The Alpha-1 Foundation’s Honor Gallery salutes the individuals, corporations, and foundations that share our commitment to finding a cure for Alpha-1 Antitrypsin Deficiency and to improving the lives of people affected by Alpha-1 worldwide. The Foundation gratefully welcomes several new members who have supported our mission for the first time through their generous contributions.

The Foundation acknowledges the continued support of the many long-time donors who have invested in our mission through contributions, events, and workplace giving. It is with sincere gratitude and appreciation that we recognize our Honor Gallery. The following is a list of donors who contributed $500 or more between July 1, 2021 and June 30, 2022.

<table>
<thead>
<tr>
<th>Amount</th>
<th>Donors</th>
</tr>
</thead>
<tbody>
<tr>
<td>$2.5 Million or More</td>
<td>AlphaNet, Inc.</td>
</tr>
<tr>
<td></td>
<td>CSL Behring, L.L.C.</td>
</tr>
<tr>
<td></td>
<td>Grifols</td>
</tr>
<tr>
<td></td>
<td>Takeda Pharmaceutical Company</td>
</tr>
<tr>
<td>$1 Million - $2,499,999</td>
<td>Anonymous Donors</td>
</tr>
<tr>
<td></td>
<td>BioMarin Pharmaceutical, Inc.</td>
</tr>
<tr>
<td></td>
<td>Jon E. Hagstrom</td>
</tr>
<tr>
<td></td>
<td>Kamada, Ltd.</td>
</tr>
<tr>
<td></td>
<td>Judith M. Kay</td>
</tr>
<tr>
<td>$500,000 - $999,999</td>
<td>Estate of James L. Fermoile</td>
</tr>
<tr>
<td>$250,000 - $499,999</td>
<td>Estate of Gerald C. and Helen M. McDonough</td>
</tr>
<tr>
<td></td>
<td>Vertex Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>$100,000 - $249,999</td>
<td>Janie Trimble</td>
</tr>
<tr>
<td>$25,000 - $99,999</td>
<td>Accredo Health</td>
</tr>
<tr>
<td></td>
<td>Anonymous Donors</td>
</tr>
<tr>
<td></td>
<td>Midge and Greg Bertles</td>
</tr>
<tr>
<td></td>
<td>Estate of Robert Duncan Brown, III</td>
</tr>
<tr>
<td></td>
<td>Ruth and Gordon E. Cadwgan, Jr. PhD</td>
</tr>
<tr>
<td></td>
<td>Columbia University Medical Center</td>
</tr>
<tr>
<td></td>
<td>CVS Health</td>
</tr>
<tr>
<td></td>
<td>Meta Payments, Inc.</td>
</tr>
<tr>
<td></td>
<td>Fred M. Odorn</td>
</tr>
<tr>
<td>$25,000 - $99,999</td>
<td>Anonymous Donors</td>
</tr>
<tr>
<td></td>
<td>BioMarin Pharmaceutical, Inc.</td>
</tr>
<tr>
<td></td>
<td>Jon E. Hagstrom</td>
</tr>
<tr>
<td></td>
<td>Kamada, Ltd.</td>
</tr>
<tr>
<td></td>
<td>Judith M. Kay</td>
</tr>
<tr>
<td></td>
<td>Austin Locke</td>
</tr>
<tr>
<td></td>
<td>Mereo BioPharma Group, PLC</td>
</tr>
<tr>
<td></td>
<td>Wendy Becker Payton</td>
</tr>
<tr>
<td>$10,000 - $24,999</td>
<td>Barbara Poresky</td>
</tr>
<tr>
<td></td>
<td>Mark Reschly</td>
</tr>
<tr>
<td></td>
<td>Elisabeth and Alan P. Sklar</td>
</tr>
<tr>
<td></td>
<td>The Benevity Community Impact Fund</td>
</tr>
<tr>
<td></td>
<td>The B.T. Rocca, Jr. Fund</td>
</tr>
<tr>
<td>$5,000 - $9,999</td>
<td>William Gundry Broughton Charitable Private Foundation, Inc.</td>
</tr>
<tr>
<td></td>
<td>Bloomberg Philanthropies</td>
</tr>
<tr>
<td></td>
<td>Drs. Sarah and Aaron Cohen</td>
</tr>
<tr>
<td></td>
<td>Kenneth A. Irvine</td>
</tr>
<tr>
<td></td>
<td>William Irvine and Gillian Marcott</td>
</tr>
<tr>
<td></td>
<td>Peg and Peter Iverson</td>
</tr>
<tr>
<td></td>
<td>Holly Jackson</td>
</tr>
<tr>
<td></td>
<td>Gerald D. Lashway</td>
</tr>
<tr>
<td></td>
<td>Linden Advisors, LP</td>
</tr>
<tr>
<td></td>
<td>National Philanthropic Trust- Ann Linnett Pless</td>
</tr>
<tr>
<td></td>
<td>Novo Nordisk</td>
</tr>
<tr>
<td></td>
<td>Barbara Perreault</td>
</tr>
<tr>
<td></td>
<td>Pivot Design</td>
</tr>
<tr>
<td>$2,500 - $5,999</td>
<td>Lauren and Faron Schonfeld</td>
</tr>
<tr>
<td></td>
<td>Lyle D. Schutte</td>
</tr>
<tr>
<td></td>
<td>Judith and Kenneth Simon</td>
</tr>
<tr>
<td></td>
<td>The Old Stones Foundation, Inc.</td>
</tr>
<tr>
<td></td>
<td>Carolyn P. and Matthew Vanderberg</td>
</tr>
<tr>
<td></td>
<td>Barbara S. Walker</td>
</tr>
<tr>
<td></td>
<td>Robert B. Webster</td>
</tr>
</tbody>
</table>
AmazonSmile Foundation
Anonymous Donors
Arcadia Healthcare Solutions
Iris Arnowitt
Bank of America Charitable Foundation
Peter A. Basile
Ruth Berkelman, MD
Helen Beuke
Charles Bissell
Scott Blackburn
Laura Bohn
James L. Braunstein
Breathless Wines
Heidi and Jon Breyer
Chris A. Bucek
Helen E. Bueker
Anthony Callea
Erin L. Carr
John M. Carter
Estate of Donald J. Ceppi
Mary M. Chilton
Rosemary B. Chiodo
Jan and Michael Chnupa
Donna A. Clark, R.N.
Kathryn W. and Daniel C. Coffin
Jane-Ellen and Joseph Collins
Joan and Curts Cooke
Timothy J. Craig, D.O.
Creating Healthier Communities
Barbara E. and Don E. Davis, Jr.
Connie A. DeWald
James F. Donohue, M.D.
Sally D. and John H. Dorf
EchoStor Technologies- Michael McMillan
Traci and Steven Egly
Erickson Solutions Group, Inc. - Peter R. Latessa
Evolve Biologics
Susan W. and Donald C. Ferro
Janet and Kenneth N. Findley
Louis G. Fox
Anne and Paul Friedlander
FrontStream Workplace Platform
Gain Therapeutics
Donna A. and James A. Geurink
Barbara A. Glenn
Monica P. Goldklang, MD
Google, Inc.
Goose the Market- Mollie and Chris Eley
Anne and Gary Greenwood
Michael B. Griffith
John E. Haffty
Patrick Haller
Dr. Jonathan Hamer
Mary Ann S. Hazen
HealthNet Systems Consulting, Inc.
Joanne and William Helsey
Kate and Robert Hoch
Kara L. Hodges
David R. Hoertling
Bridgette Holbrook
Patricia A. and Donald E. Janke
Melissa Johnson
Deborah H. and Richard C. Keiser
Andrew Kwatinetz
Norma I. Leising
Richard Lesher
Lynwood L. Locke
Dr. Harry Long
Catharine MacDonald
Sandra and Paul Maidment
Adam Marr
Karlyne M. Martin
John Mascavage
Medical Research Charities
Linda Mikell
Joan and Don Mill
Carolyn Sue Miller
Diane Mohr
Network for Good
Barbara K. Oman
Michael O'Mara
Cherie R. Patel
Anne L. and Michael F. Pawlowski
Laurie L. Perry
Beth E. Phillips
Ronald H. Pierce
David J. Posson
Janet and Harry Pottinger
Jean L. Puleo
David S. Pumpelly
Teri M. Quick
John R. Raben, Jr.
Raising Hope for Others
Krystyn Rawlinson
Tui and Joseph M. "Joe" Reidy
Joy C. and William J. Schaefer, Jr.
Chase and Michael Scott
Karen R. and John W. Sechrist
Richard F. Sedlak
Anita Sellers
Garrett Smith
Hillary A. and Jackson R. Stephens
Terry and James K. Stoller, MD, MS (Org.Dev.)
Pamela and Sidney Suggs
Anne D. and Rhea M. Sumpter
Estelle Tenant
Patricia L. Tew
The Barbara and Edward Netter Foundation
### Honor Gallery

The Begley Family Foundation  
The Doug and Tamra Adams Foundation  
The Ergonomic Group  
The Greater Kansas City Community Foundation-Haverty Family Foundation Fund  
The Jacob 219 Fund  
The Mulligan Family Fund- David Mulligan and Kim Arnowitt  
The Olivieri Johnston Family Foundation  
The Russell and Bornstein Family Charitable Fund  
The UK Online Giving Foundation  
Catherine Vernon  
Scott Walls  
Kay and Robert Walter  
Megan L. Watkins  
Wave Life Sciences  
Willie D. Wiggins  
Kathleen A. Williamson  
Andrew A. Wilson, MD  
Anthony Wong  
Worldcom Exchange, Inc. (WEI)- Mike Thweatt  
Julie W. Wright  
Linda and Robert Yoder  
Claudia and D.C. Young  
Your Cause, LLC  
Martin R. Zamora, MD

### $500 - $999

Anonymous Donors  
Jonathan E. Ansley  
David Baird  
Susan Barnes  
Anya-Nicole and John C. Barrett  
Beam Therapeutics, Inc.  
Julie L. Berry  
Kari F. and David Black  
Andrew Blair  
Misty and Greg P. Blessley  
Anne S. and Gary F. Brendel  
Connor J. Britt  
Lynda B. Broad  
Rollin A. Bush  
William D. Byrne, Jr.  
Sarah Camp  
Nancy M. Carlson  
Susan and Scott D. Casmer  
Courtney Collins  
Tricia Cotten  
Andy Croft  
Clarissa and Ronald G. Davidson  
Charles DeLacey  
Mark B. Delvaux  
Jennifer Duralia  
Linda and John K. Fielder  
Michael Gaeta  
Givinga Foundation, Inc.  
Mary A. and Robert L. Greene, Jr.  
Pat F. and Charles B. Griffis, Jr.  
Claude H. Guion, Sr.  
Cathey F. Henderson  
Maureen and Gene A. Hochberg  
Angela M. and Eric D. Hoglund  
Bonnie L. and David E. Hoglund  
Thomas R. Holland  
Cora M. and Kenneth D. Hoskins  
Finn Hurley  
IBM Employee Services Center  
Innovative Installations, Inc.  
Kenneth Irvine, Jr.  
Gregory P. Judge  
Christine Keen  
Paul C. Kimball  
Breonna Kusick  
Phillip J. Langlois  
Phillip R. Lauderdale  
Siobhan C. and Ryan Lestina  
Betty J. and Alan E. Liberty  
Steven E. Lindahl  
Deborah Locke  
Loyceta A. and Curtis R. Maslen, MD  
Patricia A. and Joseph E. Masterson  
Kory M. and John Matheis  
Angela T. McBride  
Victoria McGrane and David Scannell  
Becky and Jon Medved  
Mary and Robert Mendenhall  
Kristin Midthun  
Suzan and Mike Miller  
Corinne A. and Donald H. Mitchell  
Linda and Dennis L. Nelson  
Pamela S. Nicosin  
Adam Nunes  
Octapharma  
S. Richard Penni  
Sharon W. and Barnet Phillips  
John R. Ponton, Jr.  
Marla and James R. Reese  
Linda C. Renwick  
Bridget A. Reynolds  
Marcia F. Ritchie  
Robert E. Sandblom, MD  
Dorothea "Dot" and Robert A. "Sandy" Sandhaus, MD, PhD  
Scott Santarella  
Robert W. Schroff, Jr.  
Gary J. Seitz  
S.H. Bell Co.
Honor Gallery

Sharon and Arthur L. Shoener
Daniel W. Smith
Geralyn S. and Randy Smith
Chris L. Snell
Emily J. Sprague
Tampa International Forest Products, LLC-Joseph Brown
Lois and Christopher Teeter
The Cobb Family Foundation
The Schlang Fund- Robin C. Diamant
The Southcott Agency, Inc.- Michael W. Southcott
The Teagle Foundation- Gwen Robbins
Anne K. Thomas
Sylvia A. Thomson
Mr. and Mrs. Tom Tibbatts
Lawrence A. Twisdale
United Way of Chester County
United Way of the Greater Lehigh Valley, Inc.
USUWRB Surgery Wardroom
Debbie Waldrop, RN, MSN
Dr. Joan L. Walker
Janelle Wall
Pamela and Fred C. Walsh
Patricia Wampler
Doris and Adam Wanner, MD
Noel Weil
Mark D. Wewers, MD
Kathleen S. and Robert H. Whitby
Memory L. Whitlock
Susan Wilder
Eric Williams
Donna Womack
Peter Worley
Yecuris, Inc.
Wendy and William Zabel

Denotes Deceased
The Alpha-1 Foundation received donations in memory of the following individuals between July 1, 2021 and June 30, 2022.

Kevin J. Ahearn  
Ann M. Alciatore  
Alpha Angels  
Judith L. "Judy" Anderson  
Kenneth J. "Bo" Anderson  
Lars A. Anderson  
Melvin B. Anderson  
Robert Anderson  
Fred Ashmore  
Claire M. Aspen-Sullivan  
Michael W. Axsom  
Arlynn Baber  
Sandra E. Bain  
Kenneth A. "Kenny" Bakaitis  
Judith "Julie" Crowell Bakula  
Magnus Ball  
Nancy H. Barnhart  
Kathleen E. (Deegan) Barone  
Dorothy and Michael J. Barth  
Dwayne A. Bates  
Merle J. Baumhover  
Jan R. Bausinger  
William M. Bell  
Colin Bender  
Dwight D. "Ben" Bender  
David R. Bennett  
Edward B. "Eddie" Berman  
Susan K. Binnall  
Ann Clement Black  
Hilliard M. "Mike" Blair  
Mary J. "Jane" Blair  
Karen E. Blunt  
Grant W. Boam  
Richard A. "Rick" Bohn  
James L. "Jim" Boling  
Kenneth Bourgois  
Edward H. "Ed" Brailey  
Mary B. Braswell  
Alice K. Brazil  
James "Jim" Brenna  
Rosalie A. Brosz  
Cindy M. Bruntz  
Richard A. "Dick" Bueker  
Robert C. Bueker  
Sally J. Bulton  
John O. Byrne  
Pilar Cabiya  
Amelia Cabiya-Martinez  
Gordon E. Cadwgan, Sr.  
Robert C. "Bob" Campbell  
John P. Cannan  
Kenneth S. Carothers  
Carolyn J. Carter  
Benjamin C. Cash  
Nina Castaneda  
Anthony Castellone  
Stanley J. Castle  
George E. Catanakis  
Donald J. Ceppi  
Francis A. and Marion A. Ceppi  
Sharon Ceroll  
Gary "Chris" Christensen  
Niels Christensen  
Charles Christy  
Constance J. "Connie" Chura  
Teresa Cimino  
Tommy Clayburg  
Terry L. Cleaveland  
Benjamin J. Cochrane  
Nancy J. Coleman  
Albert "Curts" Cooke  
James P. Cooke  
Roger F. Cooper, III  
Stephen E. Cooper  
Dennis Cosgrave  
Joe Cosgrave  
Casey S. Coulson  
Robert Covington  
Fred G. Crabb  
Victoria D. "Vicki" Cronk  
Noah D. Crouch  
Evangeline J. Curtis  
Joseph Danley  
Robert "Bob" Daughtridge  
David R. Davis, Sr.  
Donald E. Davis, Sr.  
Eunice G. Davis  
Steve Dawson  
Rich P. Dean  
Elaine M. Decker  
Frank Deford  
Kenneth S. "Ken" DeSieghardt  
Lois S. DeSimone  
Michael E. DeWald  
Florence Dexter  
Patricia Dix  
Colleen Dobbs  
Michael J. Doolittle  
Reginald Dorff  
Randy Ervin Dossat  
Robert J. "Bob" Doughty  
Thomas John Downie  
Michael R. Duffy  
Laureen Dunton  
Kirk R. Dye  
Nita L. Dykes  
Mary Etter  
Sarah E. "Sally" Everett, Esq.  
Jeremy E. "Cheetah" Fahey  
Donald Fairey  
Ralph Farrar  
Martha J. Faust  
Curtis Fendley  
Nancy Ferguson  
Frank E. Fern  
Allan R. Fetters  
Nancy B. Feuerbach  
Ron Fields  
Joyce Finch  
Francis "Frank" Finnegan  
Dennis "Denny" Fisher  
Sarah Follett  
Philip M. Foster  
Vernon D. Fowler  
David Frang  
Karen L. Fraser  
Ron Fraser  
William Fraser  
Andrew A. Fredericks  
Seymour Freedman, MD  
Richard J. Fricke  
Sharon S. Friedman  
Roger Fruchey  
Sam Fullerson  
Julie Gaither
In Memory Of

Cheryl Galttana
Alexandra P. "Lexie" Gardner
Ray Gastgeb
Robin L. Gatzimos
Carl E. Gebhardt, Sr.
Linda M. Gelineau
Fred L. Geis
Cindy Jo Gill
James "Jim" Charles Goering
Minnie Goodlett
E. Sherman Grable, III
Frank Granfors
Roger S. Greene, Sr.
Anne D. Greenwood
Jean M. "Jeanie" Griffith
Richard "Dick" Guptill
Larry J. Haan
Mike Haas
Roy P. Hackman
Patrick L. Haggerty
Eliza Mozelle Halton
James C. Hamilton
Sharon K. Hampton-Blevins
Robert S. Haner
Eric Hansen
John D. Hanshaw
John F. Hanson
Robert A. Hantke, Jr.
JoAnn R. Harkins
B. Yvonne Harris
Sondra "Ruth" Harrity
James P. "Jim" Hawkins
Dorothy "Dottie" Hayes
Thomas C. Hazen
Nancy Hearte
Gregory Heath
John Heidema
Thomas M. Helms
Daniel "Dan" Henderson
Andrea "Andi" Henry
Pamela Herman
Julia Hernandez
James P. "Jimmy" Herrin
Rebecca Hicks
Richard Higby
Terrance "Terry" Highland
Steven C. Hildreth
Shaylynne S. Hill
Charles R. Hillegass
John C. Hirschi
James "Jim" Hixon
Timothy "Tim" Harry
Holdeman
Dianna L. Holt
Jesse K. Hook
Rhonda Moore Hook
Candace Hopkins
Diane "Katie" Hopp
Jeffrey Scott Horsak
Richard W. Horsak
Tony and Keny Hoskins
Kenneth and Scott Houchin
Gregory J. Hules
Jackie Hutzell
Susan A. Hyatt-Caiaccio
Catherine L. Illian
Bettina B. Irvine
Donald A. Iwen
Patricia L. Jackson
Carol B. Jankowski
Peggy Jensen
Kenneth L. Jespersen
Mary J. Johnson
Donald Johnston
Victoria T. "Vicki" Joseph
David O. Joyce
Oliver James Joyce
Alan Kaplan
Russell Kaylor
Margaret "Peggy" Keith
Catherine M. Kelley
Arno D. Kester
Kenneth F. Kiernan
Brenda Kilner
David R. Kinnius
William S. Kirk
Cindy C. Kirkeby
Helen Kline
Jack L. Koenig
Jeffrey L. Koenig
Lorraine J. Kordis
Doris V. Kramer-Roberts
Edward N. Krakels
Linda V. Krumel
Helen and Robert Kukura
John E. Kushner
Nancy J. Kutzler
Jane Lambert
Wanda S. Lambert
Jerome L. "Jerry" Lange
Margaret M. Langlois
Paul LaPorte, Jr.
Thomas E. Largura
Deborah A. Lashway
Elsa A. Lauten
Sandra L. Lawrence
Robert Lee
Gregory C. Leigh
Stephen B. Lender
Robert A. Leslie
David E. Lewis
Margaret Lewis
Sandra Lewis
Alexandra J. "Sandy" Lindsey,
Co-Founder
Lynda Clare Lindsey
Nicholas B. Linnenberger
Michael D. Livingood
Michael G. Locke
Wanda Logsdon
Lorna Lomack
Maria E. Loss
Lynn M. Lothian
Ricky Dale Lough
Robert "Randy" Lyon
Daniel B. MacArthur
Patricia E. MacInnes
Robert C. Maffit
James P. Mara
Lynette Marcum
Stacy C. Marcum Greinwald
Shirley L. Marnett
Gayle Marriott
Thomas L. Martin
Tonya L. Mashek
Judi R. Matich
Gracie Mattocks
Don McAmis
Cynthia A. "Cindy" McAndrews
Alyce Mae (Carlson) McCord
Mark D. McAuliffe
Robert D. McAuliffe
Michael L. McCamy
Gary J. McCarthy
William "Billy" McClellan
Ames McKinsey
Stanley M. McLeod
Kevin A. McMackin
In Memory Of


In Memory Of

Richard L. Teunissen
Peter M. Thomson
Suzanne Tierney
Gayle A. Tipper
Gerald “Jerry” Treichel
Kevin M. Treu
Louis "Buzz" Trevathan
James A. “Jim” Trimble
Steven Trost
Lon E. Tryggestad
Roslyn Upoff
Cathy Urish
Ivana Vandenberg
Kenneth Ver Haagh
Ken Vickers
Barbara Visser
Ed Von Kattengell
Manolo Vuelta
Denis Vuelta-Alvarez
Lela S. Wagnon
Joel C. Walcott
Helen Chase and Jack "Coach" Walsh
John W. Walsh, Co-Founder
Nancy Watson
Howard Werdehoff
Betty Westbrook
Virginia L. "Ginny" White
Loyce B. Whitlock
Ralph "Steve" Whitlock
Wilbur A. Whitlock
Karen Wiggins
Doug Wiles
Joan Willert
Patricia G. Williams
Raymond S. Wilson
Thomas B. "Buzz" Witt
Gerald C. Wolcott
Scott S. Worlton
Jackie L. Wriston
Willogene Wriston
Terry L. Young
Dr. Wayne S. Young
William E. Young
Joseph G. "Joe" Yout
In Honor Of

The Alpha-1 Foundation received donations in honor of the following individuals between July 1, 2021 and June 30, 2022.

All Alphas
Shirley J. Allen
Alpha-1 Foundation Staff
Alpha-1 Research Doctors
AlphaNet Coordinators
Alphas for Building Friends for a Cure
Ann Amoroso
Karen K. Anderson
Dwayne A. Bates
The Beck Siblings
Wendy Becker Peyton
Thomas K. Bell
Daniel J. Beltrani
Kenneth E. Benson
Kari F. Black
John S. Bradley
Mark L. Brantly, MD
Thomas A. Brown, Jr.
Jennifer and Tony Browne
James D. Buckley
Ruth and Gordon E. Cadwgan, Jr., PhD
Caregivers of Alpha Patients
Judith A. Carline
Kiara Casmer
Bianca, Chase & Ava Castillo
Marcia M. Chapter
McKinley Chittick
Lorraine Cimino
Ella and Nathan Cohen
Karl F. Cook
Albert “Curts” Cooke
Elaine A. Croucher
Jeanine D’Armiento, MD
Darlene A. Dartt, PhD
Barbara E. and Donald A. Davis, Jr.
Andrew DiDomenico
Delores A. Dissinger
Steve R. Donovan
Caden Dorfman
Karen L. Erickson
Justin Everett
Eileen L. Fern
Susan and Donald C. Ferro

Ben and Jill Fleming
Louis C. Fox
Gregory Frank
Paul Friedlander
Katherine A. Gallop
Kurt Gamlin
Brady Garcia
Catriona L. Garry
Ted Geiger
Monica P. Goldklang, MD
Joanne and Joseph Gonzalez
Ginny Green
Robert L. Greene, Jr.
Daniel F. Grimm
Patricia Hager
Jon E. Hagstrom
Melissa M. Hall
Jennifer and Matt Harader
Rebecca and Gary Harmon
Nichelle N. “Nikki” Hayes
Linda L. Hazelbeck
Jeffery L. Hildebrandt
Marion and Larry Hoffman
Gary Hoffmeyer
The Hoglund Family
Debbi Howells
Mary Hughes
Kenneth A. Irvine
Abby Jameson
Jeffrey E. Jewell
Christine Johnson
Danielle M. Johnson
Lois L. Johnson
Grace and Lucas Johnson
James M. Keith
Peter S. Kelley
Debby Kelly
Lisa A. Kosak
Dorothea L. “Dee” Kroecker
August Eskered Kroll
Victor L. Kroll
Constance “Connie” Lilly
Elizabeth "Ellie" Lindloff
In Honor Of

Kaitlyn "Katie" Lindloff
Larry Lindsey
Starr B. Locke
Dr. Harry Long
Brian Lowery
Julie MacNiel
Ricky A. Maddox
Jonathan "Money Maker" Maidment
Karen and David Maidment
Gillian L. Marcott and William Irvine
Ren, Harmony and Melody Marcum
Melissa Marko
Donna Marley
Robert E. "Bob" Martens
The Maslen Family
Patricia "Patsy" and Joseph E. Masterson
Wendy and Keith McKenna and Sons
Jim McVey
Bruce A. Miles
Nancy L. Moga
Isla R. Monti
Griffin P. Morris
Julie Murray
Elizabeth Myers
Bryan D. Nelson
Martha Nevergold
Patricia Nevergold
Robert B. Nichols
Terry R. Nickerson
Miriam A. O'Day
Sharon H. Pacelli
Scott Parks
Kenneth Pease
Debbie Peltzer
William Perry
Emilie M. Redpath
Joseph M. "Joe" Reidy
Patrick J. Reynolds
Sam Reynolds
Clarissa D. Riely
Ethan Roehrich
Dorothea “Dot” and Robert A. “Sandy” Sandhaus, MD, PhD
Ana Santos
Cameron Sapp
Bardie Scarbrough
Joy C. Schaefer
Jacob Schut

Carol Ann Shipp
Steven J. Snyder
Lynn Soriano
William T. Spilker
Cynthia and Donald J. Stagg
Harrison Clay Stephens
Ronald A. Stephens
James M. Stocks, MD
Charlie Strange MD
Sam Talarico
Lawrence Tandol
John W. Thiesen
Kenneth J. Thime
Michael G. Thomas
Jonas Tretter
Beckett James W. Van Dijk-Smith
Carolyn P. Vanderberg
Kitty Vieth
Diane L. Walsh
Juba Walsh
Pamela and Fred C. Walsh
Warren E. Waterman
Virginia E. "Ginger" Watkins
John C. "Jay" Whitmore, Jr.
Robert N. Williams
James K. Wilson, III
Casey Wolff
Joshua C. Wolff
Matthew Wolff
Michael Wolff
Marian M. Yasuda
Claudia and DC Young
Caroline L. Zeigler

Denotes Deceased
The Alpha-1 Foundation is committed to finding a cure for Alpha-1 Antitrypsin Deficiency (Alpha-1) and to improving the lives of people affected by Alpha-1 worldwide.

The Alpha-1 Foundation has invested over $91 million to support Alpha-1 research and programs at 123 institutions in North America, Europe, the Middle East, and Australia.

www.alpha1.org
1 (877) 2 CURE A1 | 1 (877) 228-7321